[1] 国家药典委员会. 中国药典一部[S]. 北京: 中国医药科技出版社, 2015:72. [2] 顾晓明, 张圆, 张晓卫, 等. 牛蒡的化学成分及药理作用研究进展[J]. 现代生物医学进展, 2013,13(16):3179-3182. [3] 张兴德, 张彩琴, 刘启迪, 等.牛蒡子抗肿瘤活性成分及作用机制研究进展[J].中国现代中药, 2012,14(12):12-17. [4] 曹旭, 曹剑锋, 陈靠山. 牛蒡的药理作用研究进展[J]. 中国现代应用药学, 2012,29(11):975-979. [5] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?[J]. Nat Rev Drug Discov, 2004,3(8):711-715. [6] Boverhof D R, Zacharewski T R. Toxicogenomics in risk assessment: applications and needs[J]. Toxicol Sci, 2006,89(2):352-360. [7] Luhe A, Suter L, Ruepp S, et al. Toxicogenomics in the pharmaceuticalindustry: hollow promises or real benefit? [J]. Mutat Res, 2005,575(1-2):102-115. [8] Foster W R, Chen S J, He A, et al. A retrospective analysis of toxicogenomicsinthe safety assessment of drug candidates[J]. Toxicol Pathol, 2007,35(5):621-635. [9] Stevens J L, Baker T K. The future of drug safety testing:expanding the view and narrowing the focus[J]. Drug Discovery Today, 2009,14(3-4):162-167. [10] Redfern W S, Ewart L, Hammond T G, et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle[J]. The Toxicologist , 2010,114(1):235. [11] ICH. ICH Guidance for Industry ICH S7A:Safety Pharmacology Studies for Human Pharmaceuticals[EB/OL]. (2000-11-08)[2015-12-20].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf. [12] 张颖丽,李芊芊,齐卫红,等. 清醒Beagle犬安全药理心血管呼吸遥测系统验证研究[J]. 中南药学, 2014,12(5):393-396. [13] 李欣, 姚景春, 高雷, 等. 功能观察组合试验(FOB)评价牛蒡子苷元对大鼠中枢神经系统的影响[J]. 中华中医药学刊, 2015,33(2).441-443. |